Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%.
Introduction
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence (1, 2) . Through the efforts of the Intergroup Rhabdomyosarcoma Study Group, and now the Children's Oncology Group, patients are stratified into low-, intermediate-, and high-risk populations based on clinical ''grouping, '' which takes into account extent of disease and surgical resection, and clinical ''staging, '' which takes into account anatomic site of disease (1) . Tumor histology has emerged as a significant predictor of outcome, as patients with the embryonal variant of rhabdomyosarcoma [termed embryonal rhabdomyosarcoma (ERMS)] generally have a better outcome than those with the alveolar type [termed alveolar rhabdomyosarcoma (ARMS); ref . 1] . Histology has thus been incorporated into the risk stratification (e.g., low-stage, low-group ARMS cases are shifted to intermediate risk because of this histology). A cytogenetic hallmark of ARMS is the reciprocal translocation of chromosomes 2 and 13, which fuses in-frame the DNA binding domain of the transcription factor PAX3 with the transactivation domain of the transcription factor FKHR , resulting in the PAX3-FKHR fusion gene (3, 4) . This chimeric transcription factor retains the DNA-binding specificity of PAX3 but is much more potent due to the altered transactivation function of the FKHR moiety (reviewed in ref. 5 ). The expression of PAX3-FKHR in metastatic ARMS portends a particularly poor outcome, with a 4-year survival of only 8% (6) . Because of its unique expression in ARMS, PAX3-FKHR continues to be a desirable target for therapeutic purposes (7) .
Elucidating the specific roles of PAX3-FKHR in rhabdomyosarcoma tumorigenesis has been challenging. Early studies of PAX3-FKHR were done in avian and rodent cell lines and suggested that PAX3-FKHR was a dominant-acting oncogene that induced transformation (reviewed in ref. 5) . The mechanism of transformation is not clear, because although PAX3-FKHR was found through microarray analysis to reactivate myogenic transcription programs (8) in a manner similar, but not identical to the neural/ skeletal muscle lineage-control gene PAX3, this reactivation alone is not adequate to transform cells. 6 Later studies, based on the ectopic expression of PAX3-FKHR in various murine and human ERMS cell lines, suggested that it could have either stimulatory or inhibitory effects on cell proliferation and apoptosis (5) , and in some cases was frankly cytotoxic (9) . These conflicting data may reflect the differential effects of PAX3-FKHR depending on the context of its expression, including level of expression and cellular milieu. Indeed, expression of other oncogenes, such as c-MYC and RAS, can have very different phenotypic consequences depending on the cell type and cellular milieu in which they are expressed (10) . As such, we reasoned that cell type might be a very important consideration when investigating PAX3-FKHR function.
We have recently developed a human cell model for rhabdomyosarcoma, in which primary human skeletal muscle cell precursors are converted to their tumorigenic counterpart by the serial introduction of a defined set of genetic changes that corrupt the p53, RB, MYC, telomerase, and RAS pathways (11) . In this system, conversion of primary human prenatal skeletal muscle cell precursors causes tumors with some features of rhabdomyosarcoma, whereas conversion of primary human postnatal skeletal myoblasts causes tumors resembling ERMS, strongly suggesting that the starting cell type affects rhabdomyosarcoma histology. As these primary human skeletal muscle precursors could be converted to a tumorigenic state identical to rhabdomyosarcoma, we reasoned that these cells might be the very ones in which the PAX3-FKHR oncogenic functions would be manifested. We therefore evaluated the consequences of expressing PAX3-FKHR in a cell type most relevant to rhabdomyosarcoma, human cells of skeletal muscle origin.
Materials and Methods
Generation of cell lines and evaluation of proliferative capacity. Early passage normal human fetal skeletal muscle (SKMC) cells (Cambrex Corp.) grown in defined media (Clonetics SkGM Bullet kit) were stably infected and selected for drug resistance with amphotrophic retroviruses derived from pK1-PAX3-FKHR, p16INK4AshRNA in pSUPER-retro-GFP-neo, wild-type (WT) p16INK4A, or vector control. Cells were selected in 0.25 Ag/ mL puromycin (Sigma) or 50 Ag/mL hygromycin B for 7 days, or 250 Ag/mL G418 (Life Technologies Invitrogen) for 10 days. The first confluent plate after drug selection for the last transgene was designated pd0. SKMCs were defined to be of skeletal muscle origin by the vendor's routine characterization using immunofluorescent staining, which was positive for sarcomeric myosin. Human skeletal muscle myoblast (HSMM) cells were characterized by the vendor as >60% positive for desmin stain at first passage out of cryopreservation, although the lot used in these experiments was >90% desmin positive. IMR90 cells were grown in DMEM/F12 (1:1) with 15% fetal bovine serum (FBS). Human rhabdomyosarcoma cell lines were grown in RPMI 1640 with 10% FBS.
Immunoblotting. Cell lysates were prepared by homogenization in Tris/ radioimmunoprecipitation assay buffer with standard protease inhibitors and passage through a 21-gauge needle to shear DNA. Protein concentration was measured by the Bio-Rad detergent-compatible protein assay (Bio-Rad). Each lysate (60-100 Ag) was resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and immunoblotted with primary monoclonal antibodies anti-FOXO1A F6928 (Sigma), anti-p16 INK4A (BD PharMingen), anti-desmin M0760 (DakoCytomation), anti-muscle-specific actin M0635 (DakoCytomation), anti-actin SC-8342 (Santa Cruz Biotechnology), or anti-tubulin T-4026 (Sigma), reacted with a secondary horseradish peroxidase (HRP)-labeled goat anti-mouse antibody (Amersham Biosciences) and developed using chemiluminescence (Amersham Biosciences). The anti-FOXO1A antibody was generated against the COOH terminus of FOXO1A (also known as FKHR) protein and therefore recognizes not only FKHR (f70-80 kDa) but also the PAX3-FKHR fusion, which shows a mobility shift (f100-110 kDa) in our system. This article does not address the biological significance of changes in FKHR; FKHR bands were only included in the figures to provide molecular weight reference.
Analysis of p16 INK4A promoter methylation and allelic loss. Analysis of INK4A promoter CpG island methylation and INK4A allelic loss was done using methods described (12) .
Differentiation assays. Growth media of f60% confluence HSMM cell cultures were replaced with fusion media (DMEM/F12 with 2% horse serum) and refreshed every other day for f5 days. Myotubes were rinsed with PBS, fixed with cold 70% ethanol/formalin/glacial acetic acid (20:2:1), rinsed again with PBS, and permeabilized for 10 min with 0.10% NP40 in 10 mmol/L Tris (pH 7.4) and 150 mmol/L NaCl. For primary antibody binding, myotubes were first blocked for 30 min with 10% horse serum in PBS, incubated for 1 h with anti-sarcomere-myosin hybridoma MF20 (13) , and then rinsed with PBS Â 3 for 10 min. Primary antibody binding was detected by incubation for 30 min with biotinylated anti-mouse IgG [diluted to 5 Ag/mL in PBS-0.10% bovine serum albumin (BSA)], rinsing with PBS Â 3 for 10 min, incubation for 30 min with HRP-streptavidin (diluted to 4 Ag/mL in PBS-0.10% BSA), and then rinsing with PBS Â 3 for 10 min. A final 5-min incubation was done with 3,3 ¶-diaminobenzidine reagent followed by a water rinse, rendering the antibody binding as brown-black.
Analysis of tissue microarrays by immunohistochemistry. Human ERMS and ARMS tumor tissue microarrays (TMA) were obtained from the Cooperative Human Tissue Network, which is funded by the National Cancer Institute, with prior Institutional Review Board approval. The ERMS TMA contained 60 cores derived from 21 unique cases; the ARMS TMA contained 31 cores derived from 13 unique cases. Human p16 INK4A expression was evaluated using the CINtec p16 INK4A Histology kit as described by the manufacturer (DakoCytomation). Normal human tonsil tissue was used as an external positive control, and an isotype-specific antibody was used as a negative control. As internal positive controls, companion slides were analyzed (and showed 100% staining) for expression of MyoD1 and myogenin to prove intact antigenicity (14) .
Statistical analysis. Tissue cores were evaluated by C.K. and S.Q. and scored for p16
INK4A staining using a system reported previously (15) . Only nuclear staining was considered positive and was graded as follows: 0, negative stain; 1+, rare isolated nuclei positive; 2+, V10% nuclei positive; 3+, >10% but <50% nuclei positive; and 4+, z50% nuclei positive. Because some cores were replicates from the same tumor, and showed variable staining, these replicate scores were averaged to generate a final score for each unique tumor. A two-sample Wilcoxon test was used to compare the scores from the ERMS and ARMS groups.
Results
PAX3-FKHR drives normal primary human skeletal muscle cells past the senescence checkpoint. To evaluate the phenotypic consequences of PAX3-FKHR expression in primary human cells of skeletal muscle origin, a cDNA encoding its full-length sequence was stably expressed in primary human prenatal SKMCs using amphotrophic retrovirus. Because primary SKMCs senesce in culture after 15 population doublings, experiments were initiated in low passage (pd2) cells. Before genetic manipulation, SKMCs were verified to express desmin, one of the protein markers supporting skeletal muscle origin (Fig. 1A, top) . Following selection for retroviral insertion, the resulting cell lines were examined for appropriate transgene protein expression (Fig. 1A, bottom) ; the level of expression of PAX3-FKHR protein was similar to that expressed by two human ARMS cell lines, JR and Rh28. SKMCs expressing PAX3-FKHR (SKMC PF ) or vector control (SKMC V ) were then monitored in culture for changes in their proliferation or morphology. Within 1 month, SKMC V cells slowed their proliferative rate and acquired morphologic signs of senescence, including cell spreading, flattening, and granularity, with complete cessation of proliferation of two population doublings following the transduction of the last retroviral vector (Fig. 1B, o) . Although the SKMC PF cells generally showed a slowing of proliferation, the culture was eventually overtaken by microcolonies of small, refractile cells that eventually dominated the culture and continued proliferating past the predicted senescence checkpoint (Fig. 1B, . ).
These cells were termed ''post-senescent '' because they proliferated past the senescence checkpoint that classically leads to the growth arrest of primary cells in culture. This type of bypass suggests that a primary cell population has overcome the growthinhibitory stress signals of culture in an artificial environment (16) .
To assess the reproducibility of this phenomenon, a second type of primary human skeletal muscle cell, known as postnatal human skeletal muscle myoblasts (HSMM) cells, was similarly studied. Low passage cells were verified to be of skeletal muscle origin, as shown by expression of desmin and skeletal-muscle-specific actin (Fig. 1A,  top) , stably infected with retrovirus encoding PAX3-FKHR or an empty vector, and validated to express PAX3-FKHR at a protein level similar to other human ARMS cell lines (Fig. 1A, bottom) . Population doublings were monitored over time to assess the proliferative life span of the cells. In agreement with others (9), ectopic expression of PAX3-FKHR initially caused some inhibition of proliferation compared with vector control, but expression was overall tolerated. The proliferation of HSMM V cells plateaued at about pd15-19 (Fig. 1C, o) , whereas HSMM PF cells exhibited a slight delay at this point, but nevertheless proliferated past the senescence checkpoint (Fig. 1C, . ) and continued log-phase growth. As with the SKMCs, HSMM PF cells bypassing senescence acquired a proliferative appearance with refractile cells in mitosis (Fig. 1D, left) , whereas HSMM V cells slowed their growth rate and adopted a senescent morphology (Fig. 1D, right) . After months of senescence, this population seemed to resume proliferating, albeit at a very slow rate. To determine whether the expression of PAX3-FKHR similarly enabled a nonskeletal muscle primary human mesenchymal cell type to bypass senescence, IMR90 human fetal lung fibroblast cells, which usually senesce at about 50 population doublings, were infected with retrovirus encoding PAX3-FKHR or empty vector. Both cell lines were able to be generated, indicating successful integration of the retrovirus. However, both cell lines senesced, the IMR90
Vector at about pd52 and the IMR90 PAX3-FKHR at about pd36 (data not shown). Last, in agreement with others' observations that PAX3-FKHR can be toxic, we found that although we could express an empty control vector in HT1080 fibrosarcoma cells, PAX3-FKHR expression was not tolerated.
In summary, we found that stable expression of PAX3-FKHR in two types of primary human skeletal muscle cell precursors, SKMC and HSMM cells, enabled them to proliferate past the senescence checkpoint. Stable expression of PAX3-FKHR in a human nonskeletal muscle primary mesenchymal cell type was tolerated but did not enable bypass. Stable expression in a human nonskeletal muscle mesenchymal tumor cell line was toxic. Thus, the phenotypic consequences of PAX3-FKHR expression is cell type specific, and a novel oncogenic function for PAX3-FKHR , bypass of the senescence checkpoint, was revealed when this protein was expressed in the most relevant cells for this disease, human skeletal muscle cells. PAX3-FKHR-mediated bypass of cellular senescence is accompanied by loss of the tumor suppressor p16 INK4A . Having established that the expression of PAX3-FKHR could coax primary human skeletal muscle cells past the senescence checkpoint, we next sought to identify the molecular changes underlying this phenomenon. We hypothesized that PAX3-FKHR provided a strong proliferative signal that selected for a population of cells able to continue dividing beyond senescence. Previous studies in primary human mammary epithelial cells showed that epigenetic downregulation of the p16 INK4A tumor suppressor protein was critical in their overcoming a senescence-like state (17) and that this bypass was a step toward tumorigenesis (18) .
To investigate the possibility that an epigenetic change such as p16 INK4A silencing might be occurring in the observed PAX3-FKHR-mediated bypass of senescence, p16
INK4A protein expression was evaluated in post-senescent SKMCs expressing PAX3-FKHR. As a positive control, p16
INK4A expression was also assayed in SKMCs expressing the SV40 DNA tumor virus early region, which enables bypass of senescence via inactivation of the p53 and RB pathways, independent of p16 INK4A loss. Fig. 2A, top) , indicating no effect of PAX3-FKHR. We also considered the possibility that PAX3-FKHR was affecting p16
INK4A expression by transcriptionally activating BMI-1, a polycomb group repressor of INK4A transcription that is implicated in stem cell self-renewal but downregulated in primary cells as they senesce (20) . As expected, BMI-1 levels decreased in both SKMC and HSMM vector populations as they senesced and remained low. However, a similar loss of BMI-1 expression was seen in those cells expressing PAX3-FKHR as they approached the senescence checkpoint, indicating no upregulation of BMI-1 in the presence of PAX3-FKHR overexpression. Interestingly, after senescence bypass, both SKMCs and HSMM cells expressing PAX3-FKHR showed dramatically increased BMI-1 levels that paralleled their p16
INK4A loss, indicating that other factors must be influencing BMI-1 expression. We also found that SV40-transformed HSMM cells expressing high levels of p16 INK4A protein simultaneously expressed high levels of BMI-1 (data not shown), implicating other inputs to p16
INK4A modulation (19) . Thus, the control of the INK4A locus is complex, and although not exhaustive, these analyses provide no evidence for a trans-acting effect of PAX3-FKHR on the expression of p16 INK4A . To evaluate for homozygous allelic INK4A loss, genomic DNA was isolated from HSMM cells and assayed for the presence or absence of exon 2 of INK4A, using a standard nested PCR approach (12) . In both pre-senescent HSMM V and post-senescent HSMM PF cells, PCR product was visible in both the INK4A and D9S196 reactions, indicating no homozygous loss (Fig. 2B, top) . To evaluate for heterozygous INK4A allelic loss, genomic DNA isolated from HSMM cells was assayed for the presence of three different microsatellite markers, D9S126, D9S741, and D9S1748, again using a standard PCR approach (12) . PCR product patterns were identical in pre-and post-senescent cells, indicating that at these three loci, there was no loss of heterozygosity (Fig. 2B, bottom) . Last, to determine whether the INK4A gene was transcriptionally silenced by promoter methylation of CpG islands, genomic DNA collected from both pre-senescent HSMM V and postsenescent HSMM PF cells was subject to methylation-dependent PCR; in pre-senescent HSMM V cells, the INK4A promoter was unmethylated, whereas in post-senescent HSMM PF cells, the INK4A promoter became methylated (Fig. 2C, top) . This assay was repeated in SKMCs, with similar findings (Fig. 2C, bottom) . Because the INK4A promoter was methylated in cells expressing PAX3-FKHR that had bypassed senescence, INK4A mRNA should be decreased; this was verified using reverse transcription-PCR (RT-PCR), which showed that INK4A transcription was downregulated (Fig. 2D) .
In summary, we found that in both SKMCs and HSMM cells that had bypassed senescence vis-à-vis PAX3-FKHR expression, p16
INK4A protein expression was greatly diminished, seeming to occur by transcriptional down-regulation via DNA methylation of the INK4A promoter. We hypothesize that PAX3-FKHR expression drives cells to divide sufficiently for the selection of cells with INK4A promoter methylation, thereby overcoming the senescence checkpoint.
PAX3-FKHR cooperates with p16 INK4A loss to promote bypass of senescence. Because the expression of PAX3-FKHR promoted a bypass of cellular senescence, but only in the setting of decreased p16
INK4A expression, we next explored whether PAX3-FKHR gain-of-function and p16
INK4A loss-of-function cooperated to promote bypass of cellular senescence. Specifically, a p16 shRNA alone, PAX3-FKHR alone, or infected with two empty control vectors. All four cell lines were assessed for proliferative capacity, expression of p16 INK4A and PAX3-FKHR protein, and morphology (Fig. 3) . As observed previously, the vector cells (Fig. 3A, V+V, d ) adopted a flattened, granular appearance without mitotic figures (Fig. 3C, V+V) and entered senescence, although in this experiment, a clonal population later escaped senescence and resumed proliferating after months of quiescence, in which p16
INK4A expression was again down-regulated as assessed by immunoblot (data not shown). Also as expected, after an extended period of selection, expression of PAX3-FKHR drove cells beyond senescence (Fig. 3A, PF+V, 5 ). These cells were rounded, refractile, and contained many mitotic figures (Fig. 3C, PF+V) . Consistent with the known role of p16 INK4A in the maintenance of cellular senescence, cells stably expressing the p16 INK4A shRNA also eventually bypassed senescence (Fig. 3A, V+p16 sh , x). These cells were flattened and granular but with occasional mitotic figures (Fig. 3C, V+p16 sh ). However, concomitant loss of p16 INK4A with expression of PAX3-FKHR drove cells to proliferate faster and overcome senescence with little or no lag in proliferation (Fig. 3A,  PF+p16 sh , n). These cells were rounded, refractile, and contained many mitotic figures (Fig. 3C, PF+p16 sh ). Analysis of p16
INK4A
protein expression by immunoblot (Fig. 3B) (Fig. 3D, top) , those transduced with p16
INK4A cells showed a growth arrest (Fig. 3D,  bottom) , indicating that continued down-regulation of p16
INK4A is required for persistent proliferation of these cells in the postsenescent phase. Three colonies later emerged from this cell population and were found to lack detectable p16 INK4A expression, further validating our observation that p16
INK4A expression must continue to be suppressed in post-senescent HSMM PF cells. In summary, we found that whereas ectopic expression of PAX3-FKHR, or loss of p16 INK4A , each enabled slow bypass of the senescence checkpoint, expression of PAX3-FKHR with concomitant knockdown of p16 INK4A stimulated the most rapid bypass of senescence. Expression of WT p16
INK4A at levels tolerated in other cells either immediately prior to, or after the bypass of senescence, caused acute cell growth arrest and cell death, indicating the absolute requirement for p16 INK4A loss. Thus, loss of p16
cooperates with gain of PAX3-FKHR to drive inappropriate proliferation. These data support the role for the cooperation of PAX3-FKHR gain-of-function with p16 INK4A loss-of-function in the ability of human cells of skeletal muscle origin to bypass the senescence checkpoint.
PAX3-FKHR does not promote senescence bypass by interfering with myoblast differentiation. PAX3-FKHR could
